Portal Innovation's 30,000-square-foot Helix Park lab space is open for business. Photo via Portal Innovations/X

A new life science-focused venture capital engine has officially opened offices in Houston.

Portal Innovations moved into a space at Helix Park in October. The offices are led by executive director Monique Knighten.

Knighten has been in Houston for 16 years, since she was a postdoc at the University of Texas Institute for Molecular Medicine. “It's like a lot of us. We come for a specific reason, and then we just find reasons to stay,” she says.

And now, that reason is to push the emerging Houston ecosystem forward by helping early-stage startups to build themselves toward success. Portal does that partly by providing capital, but besides cash investments, emerging companies need a physical infrastructure where their work can happen. They also need great people to support their cause at every step of development. To that end, networking and convening with beneficial people is key for Portal.

With locations already in Chicago, Boston and Atlanta, why did Portal choose Houston?

“If you take a look at where lots of scientific publications are coming from, if you look at where a lot of technology that eventually becomes commercialized, a lot of it will come initially from labs that are right here in Houston,” says Knighten. “Houston also has a great quality of life. That's really important so that startups need to be able to have a place where they can have their teams.”

And who has joined Portal in its 30,000-square-foot Helix Park lab space? March Biosciences, a cancer-focused cell therapy startup; Crossbridge Bio, responsible for a cancer therapeutic that just closed a $10 million seed round; Artidis, which is personalizing cancer diagnosis thanks to a new nanomedical biomarker technology; Spanios, which has created human model systems to help researchers better identify therapeutic options for solid tumors; Stingray Therapeutics, a cancer immunotherapy company working on metastatic or advanced solid tumors; Remunity Therapeutics, an immuno-oncology startup developing immune-stimulating antibody-drug conjugates that reactivate anti-tumor immune response; and Phiogen, which is doing promising work in the world of non-antibiotic anti-infectives.

The Cancer Focus Fund, an oncology-focused investment fund in partnership with The University of Texas MD Anderson Cancer Center is also sharing space with the burgeoning biomedical companies.

Even Texas Medical Center CEO Bill McKeon is excited to greet Portal.

“In Portal, we have a partner with a proven track record of leveraging venture capital funding, expert partners and strong programming to support dynamic, entrepreneurial businesses at pivotal moments of their growth. We look forward to building on our collective expertise and shared vision to further support the breakthroughs of early-stage life science ventures,” he says on the company’s website.

By working with Portal, each of the companies will benefit not only from Knighten’s expertise i building teams gathered from her time at Sartorius Stedim Biotech and decade with Miltenyi Biotec, but also that of the other Portal teams. Working on a national scale also gives the brands opportunities for national exposure. Just one more way, Houston’s ecosystem is continuing to move the needle both for the healthcare companies in it and the patients who will one day benefit.

Four Houston startups have received over $40 million in funding from a Texas organization. Photo via Getty Images

4 Houston life science startups secure over $40M in CPRIT funding

cha-ching

Four Houston bioscience startups have collected nearly $43 million in grants from the Cancer Prevention and Research Institute of Texas (CPRIT).

Here’s a list of the four startups, the amount and purpose of each grant, and some background information about each company.

Stingray Therapeutics

CPRIT grant amount: $13,881,458

Purpose of grant: Clinical trial to evaluate an immunotherapy known as SR-8541A for treatment of advanced or metastatic solid tumors.

Company background: Stingray received a $2 million Small Business Innovation Research (SBIR) award in 2022. In conjunction with the award, Mohan Kaadige, a research associate professor at the Translational Genomics Research Institute, joined Stringray as the principal SR-8541A investigator.

“I … believe we have great potential to alleviate cancer suffering in the near future with this exciting technology,” says Kaadige.

March Biosciences

CPRIT grant amount: $13,358,637

Purpose of grant: Clinical trial to evaluate a T-cell immunotherapy (MB-105) for treatment of certain types of relapsed lymphoma.

Company background: March Biosciences, a Baylor College of Medicine spinout, recently received $4.8 million in funding from Cancer Focus Fund, affiliated with Houston’s MD Anderson Cancer Center.

“The breadth and quality of the support we are receiving from our local partners and institutions underscore Houston’s increasing prominence as a worldwide leader in cancer R&D and clinical research,” says Sarah Hein, co-founder and CEO of March Biosciences.

Mongoose Bio

CPRIT grant amount: $10,621,053

Purpose of grant: Development of T-cell therapies targeting solid-tumor cancer.

Company background: Mongoose founder Cassian Lee, a professor and researcher at MD Anderson, is a CPRIT scholar and a participant in Texas Medical Center Innovation’s 2023 Accelerator for Cancer Therapeutics.

“Mongoose Bio is a first-rate example of the use of CPRIT funds to fund a disruptive cell gene therapy … therapeutic with deep roots and origins in Texas. This innovation will benefit patients with solid tumors not just in Texas but the rest of the world,” says CPRIT.

FixNip

CPRIT grant amount: $4,844,088

Purpose of grant: Clinical study and manufacturing of a silicone implant that creates a soft, natural-looking nipple for women with breast cancer who’ve undergone post-mastectomy breast reconstruction. The clinical study will be done at MD Anderson.

Company background: In conjunction with the CPRIT grant, FixNip is moving its headquarters from Israel to Houston. Austin-based CPRIT became aware of FixNip during a May 2022 trade trip to Israel by the organization’s CEO, Wayne Roberts.

“Loss of nipple projection is the most pervasive problem across all currently existing nipple reconstruction solutions,” says FixNip.

Aside from the grants for the four Houston startups, CPRIT handed out two grants for recruitment of two cancer researchers to Houston:

  • $6 million grant to recruit Dr. Leonido Luznik of Johns Hopkins University to the Baylor College of Medicine. Luznik’s research focuses on allogeneic blood and marrow transplantation (alloBMT), a treatment for blood cancers.
  • $1.99 million grant to recruit Swiss researcher Christina Tringides to Rice University. Tringides is working on a “groundbreaking” treatment for brain tumors, says CPRIT.
Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Uber, Nuro and Lucid plan to roll out robotaxi services in Houston

autonomous autos

More autonomous vehicles are expected to hit the roads in Houston next year.

Ridesharing giant Uber announced that it plans to roll out its premium robotaxi service in the Bayou City in mid-2027. Houston will be Uber’s second planned market for the program, following the San Francisco Bay Area, where the program is expected to be rolled out later this year.

Uber, Nuro and Lucid Group will bring the robotaxi program to Houston with more markets planned for the future. Currently, Nuro is conducting autonomous on-road testing with safety operators in Houston. Testing includes simulation, closed-course testing and supervised public-road testing.

“Houston is a city Nuro knows well, and we’re excited to help bring this robotaxi service to the city through our partnership with Uber and Lucid,” Andrew Chapin, chief operating officer at Nuro, said in a news release. “Houston’s large, complex metro area is an ideal market for demonstrating how Nuro’s universal autonomy platform can generalize across different geographies and operating environments. We look forward to continued engagement with the community as we prepare to launch service in 2027.”

The fleet of 100 vehicles across California and Texas will feature Lucid Gravity EVs and future Lucid Midsize vehicles equipped with Nuro Driver technology, Nuro’s Level 4 universal autonomy platform, plus a redundant sensor suite with cameras, lidar, radar and a roof-mounted halo.

The vehicles will be owned and operated by Uber and its fleet partners and made available to riders through the Uber network, according to the company.

In addition to the fleet of autonomous vehicles, Uber also announced that it has secured a 50,000-square-foot depot facility and dedicated charging pitstop in Houston. The facility will allow Uber and its partners to control vehicle maintenance, repairs, charging, cleaning, and day-to-day operations.

“Houston marks an important next step in our partnership with Lucid and Nuro as we expand autonomous mobility to more riders throughout the world,” Sarfraz Maredia, global head of autonomous mobility & delivery at Uber, added in the release. “Together, we’re combining best-in-class vehicle and autonomy technology with Uber’s scale, fleet operations expertise, and infrastructure capabilities to build a service that can grow across dozens of markets in the years ahead.”

Waymo launched its autonomous vehicle program in Houston in February.

The company later suspended its driverless car services in Houston, other major Texas cities, and Atlanta, after one of its vehicles was stranded by flooding during heavy rains. However, according to the Houston Chronicle, the fleet has resumed activity in Houston and is fully active.

Houston fintech company closes $7M funding round

fintech funding

Houston-based fintech company Receipts Depositary Corporation has closed a $7 million oversubscribed funding round and plans to scale.

The round was led by Austin-based LiveOak Ventures, with participation from Hivemind Capital, Onigiri Capital, OTC Markets Group, GTS, and Redbeard Ventures, according to a release from RDC.

RDC's platform issues depositary receipts (DRs) to qualified investors on digital and alternative assets, making it easier for investors to buy and trade hard-to-access and less traditional assets. Currently, the company offers DRs for cryptocurrencies including Bitcoin, Ethereum, Solana and XRP.

RDC says the new funding will allow it to launch new DR products across a wider range of asset categories, potentially including commodities. Additionally, it plans to grow its relationships with "banks, broker-dealers, market makers, custodians and exchange partners" and add to its product, operations, technology, and commercial functions teams. The company is actively hiring, according to a press release.

“Depositary Receipts are trusted, regulated capital markets products which RDC is bringing to an entirely new universe of assets, from commodities to digital assets, that have historically been out of reach of traditional securities markets," Krishna Srinivasan, founding partner at LiveOak Ventures, said the release. “The team's depth of experience in the DR business on a global scale, combined with the broad institutional validation from co-investors, anchor customers, and strategic partners across asset classes, makes RDC uniquely positioned to define this category. We're proud to lead this round and support the company as it scales.”

RDC was founded in 2022 by three Citibank alumni: CEO Ankit Mehta, CEO Bryant Kim and COO Ishaan Narain. It began offering its first DRs for Bitcoin in 2024.

“This funding round is a strong validation of what we’re building at RDC and the growing demand for modernized Depositary Receipt infrastructure,” Mehta added in the release. “With the support of LiveOak Ventures and our investor partners, we are accelerating development across our DR platform expanding our market reach, and building the team needed to support the next generation of DR product

Houston space co. adds local colleges to university alliance

space schools

Houston’s Axiom Space has added 26 new members to its University Alliance—including two from Houston—to support the next generation of space exploration.

Engineers, researchers and students from the partnering universities will be dedicated to advancing microgravity research, technology development and commercial innovation in low-Earth orbit.

Rice University and the University of Houston are among the new colleges to join the alliance, which launched with 15 members last year. The University of Texas at Austin and the University of Texas at El Paso have also joined, in addition to international institutions in Europe, Asia and Australia, and others from around the U.S. See full list here.

“Through the University Alliance, Axiom Space is uniting the international research community driven to enable human progress,” Lucie Low, Axiom Space chief science officer, said in a news release. “Together, alliance members are taking the initiative to ensure microgravity research benefits everyone on Earth and our shared goals fulfill a scientific purpose to advance civilization.”

Axiom is building the world’s first commercial space station, known as Axiom Station. The University Alliance “will support and advance space science during the transition from government-led to commercially owned and operated space stations,” the company said in a release. Partnering universities will contribute to the research community by participating in international collaborative scientific initiatives, identifying future research, and bolstering strategic positions in the commercial orbit research field.

Recently, the Rice Space Institute was also selected to lead the U.S. Space Force Strategic Institute 4 in addition to other space-centric partnerships.

“We’re excited to bring our expertise to this global alliance and to benefit from the deep expertise of our partners,” David Alexander, professor of physics and astronomy and director of the Rice Space Institute, said in a news release. “Space is truly a collaborative and global endeavor. Alliances like these are key to progress.”

UH and NASA’s Johnson Space Center expanded their collaboration in 2022. In 2024, UH launched its NASA MIRO Inflatable Deployable Environments and Adaptive Space Systems Center (IDEAS2) via a five-year, $5 million grant.

“As a major public research university located in Space City, the University of Houston has a unique opportunity and responsibility to help lead the future of space innovation, and our participation in Axiom Space’s University Alliance represents a major step forward in that mission,” Karolos Grigoriadis, the Hugh Roy and Lillie Cranz Cullen Endowed Professor and chair of mechanical and aerospace engineering at UH, added in a separate release.

Meanwhile, Axiom recently tacked on an additional $175 million to a previously announced capital raise, bringing the oversubscribed round to a total of more than $525 million. It also has announced plans to launch Swiss and Japanese subsidiaries.